(2) Required activitiesThe activities referred to in this paragraph are the following: (A) The conduct of state-of-the-art research for the following purposes:
(i) To increase awareness of—(I) new uses of drugs, biological products, and devices;(II) ways to improve the effective use of drugs, biological products, and devices; and(III) risks of new uses and risks of combinations of drugs and biological products.
(ii) To provide objective clinical information to the following individuals and entities:(I) Health care practitioners and other providers of health care goods or services.(II) Pharmacists, pharmacy benefit managers and purchasers.(III) Health maintenance organizations and other managed health care organizations.(IV) Health care insurers and governmental agencies.(V) Patients and consumers.
(iii) To improve the quality of health care while reducing the cost of health care through—(I) an increase in the appropriate use of drugs, biological products, or devices; and(II) the prevention of adverse effects of drugs, biological products, and devices and the consequences of such effects, such as unnecessary hospitalizations.
(B) The conduct of research on the comparative effectiveness, cost-effectiveness, and safety of drugs, biological products, and devices.
(C) Such other activities as the Secretary determines to be appropriate, except that a grant may not be expended to assist the Secretary in the review of new drugs, biological products, and devices.